1. Home
  2. GHRS

as of 09-04-2026 4:00pm EST

$28.23
+$0.37
+1.31%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Founded: 2018 Country:
Ireland
Ireland
Employees: N/A City: N/A
Market Cap: 2.0B IPO Year: 2021
Target Price: $41.38 AVG Volume (30 days): 252.2K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $11.83 - $31.44 Next Earning Date: 05-01-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: